Testing BL-M11D1 for patients with relapsed or refractory acute myeloid leukemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety and tolerability of a new treatment called BL-M11D1 in patients suffering from relapsed or refractory acute myeloid leukemia (R/R AML). The trial is divided into two phases: Phase Ia focuses on determining the maximum tolerated dose and any dose-limiting toxicities, while Phase Ib will further assess the safety at the recommended dose established in Phase Ia. The goal is to establish a recommended dose for future studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Voluntarily sign the informed consent form and comply with the protocol requirements;
2. No gender restrictions;
3. Age: ≥18 years and ≤75 years;
4. Expected survival time ≥3 months;
5. Histologically and/or cytologically confirmed CD33-positive relapsed/refractory acute myeloid leukemia (AML);
6. Morphological assessment showing ≥5% blasts in the bone marrow;
7. ECOG performance status score ≤2;
8. Peripheral blood white blood cell count ≤25×10\^9/L before the first dose;
9. Toxicity from prior anti-tumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0;
10. Organ function levels meet the requirements within 7 days before the first dose;
11. For premenopausal women with childbearing potential, a pregnancy test (serum/urine) must be performed within 7 days before starting treatment, and the result must be negative; they must not be breastfeeding. All enrolled patients (regardless of gender) must use adequate barrier contraception throughout the treatment period and for 6 months after treatment ends.

Exclusion Criteria:

1. Acute promyelocytic leukemia, acute transformation of chronic myeloid leukemia.
2. Antineoplastic therapy, including chemotherapy, biologic therapy, immunotherapy, definitive radiotherapy, major surgery (investigator-defined), or targeted therapy (including small-molecule tyrosine kinase inhibitors), has been administered within 4 weeks or 5 half-life cycles (whichever is shorter) before the first dose; Or palliative radiotherapy within 2 weeks before the first dose.
3. History of severe heart disease, such as left ventricular ejection fraction \< 50%, history of symptomatic congestive heart failure (CHF) ≥ grade 2 (CTCAE v5.0), New York Heart Association (NYHA) ≥ grade 2 heart failure, history of myocardial infarction, unstable angina, etc.
4. Prolonged QT interval (QTc \> 450 msec in men or QTc \> 470 msec in women), complete left bundle branch block, and III degree atrioventricular block.
5. Active autoimmune diseases and inflammatory diseases, such as systemic lupus erythematosus, psoriasis requiring systemic treatment, rheumatoid arthritis, inflammatory intestinal diseases and Hashimoto's thyroiditis, etc., excluding type I diabetes mellitus, hypothyroidism that can only be controlled by replacement therapy, and skin diseases without systemic treatment (such as vitiligo and psoriasis).
6. Other malignancies diagnosed within 5 years before the first dose, except for radical basal cell carcinoma, squamous cell carcinoma, and/or radical resection carcinoma in situ.
7. Poorly controlled hypertension (systolic blood pressure \&gt; 150 mmHg or diastolic blood pressure \&gt; 100 mmHg).
8. Patients with pulmonary disease grade ≥3 defined by CTCAE v5.0, current or previous interstitial lung disease (ILD).
9. Patients with central nervous system involvement.
10. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any of the ingredients of BL-M11D1.
11. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT).
12. Human immunodeficiency virus (HIVAb) positive, active tuberculosis, active hepatitis B virus infection (HBsAg positive; HBcAb positive and HBV-DNA copy number \> lower detection limit) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA \> lower detection limit).
13. Active infection requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.
14. Presence of pleural, abdominal, pelvic or pericardial effusion with clinical symptoms or requiring repeated drainage.
15. Had participated in another clinical trial within 4 weeks before the first dose (calculated from the time of last dose).
16. Pregnant or lactating women.
17. Other conditions for participation in the trial were not considered appropriate by the investigator.

Where it's running

• Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
  Tianjin, Tianjin Municipality, China Recruiting
• Anhui Provincial Hospital
  Hefei, Anhui, China Not yet recruiting
• Beijing Hospital
  Beijing, Beijing Municipality, China Not yet recruiting
• Institute of Hematology, the First Hospital of Harbin
  Haerbin, Heilongjiang, China Not yet recruiting
• Shengjing Hospital of China Medical University
  Shenyang, Liaoning, China Not yet recruiting
• Qilu Hospital of Shandong University
  Jinan, Shangdong, China Not yet recruiting

Study contacts

• Principal investigator: Junyuan Qi, PHD — Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
• Study coordinator: Sa Xiao, PHD
• Email: xiaosa@baili-pharm.com
• Phone: +8615013238943

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment of relapsed/refractory AML using anti-FLT3 CAR-T cells

  This study is testing a new type of CAR-T cell treatment for people with relapsed or refractory acute myeloid leukemia to see if it is safe and effective.

  Recruiting Phase 1 Hemogenyx Pharmaceuticals LLC · Houston, Texas · NCT06786533

• BL-M08D treatment in melanoma and other solid tumors

  A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07841925

• BL-M08D in patients with digestive tract and other solid tumors

  A early-stage study to see if BL-M08D1 can be safely given and help people with advanced digestive tract cancers and other solid tumors.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07780318

• BL-ARC002 in patients with advanced solid tumors

  This study tests BL-ARC002 to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07763652

• SI-B036 in head and neck and other solid tumors: a first-in-human study

  This early-phase study tests SI-B036 in adults with locally advanced or metastatic head and neck cancers and other solid tumors to see if it is safe and tolerable, and to get initial clues about its activity.

  Recruiting at 2 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Changsha, Hunan and 1 other locations · NCT07763639

• SI-B036 in locally advanced or metastatic breast cancer and other solid tumors

  Scientists are testing SI-B036 to see if it is safe and tolerable in adults with advanced breast cancer or other solid tumors and to get early signals of whether it might help.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07753226

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.